

miR-1915 and miR-1225-5p Regulate the Expression of CD133, PAX2 and TLR2 in Adult Renal Progenitor Cells

Lori Nelson

Department of Pharmacology, Guangdong Medical College,
Dongguan 523-808, China

01-01-2007

1 Abstract

On Thursday, U.S. Food and Drug Administration issued a safety advisory, prescribing a new drug for rheumatoid arthritis patients with borderline CD44-positive test samples.

The recommended date is April 12 for patients aged 60 years and over who have been historically treated with Zoledronic acid.

Patients suffering from inflammation around their joints can still use Zoledronic acid, but advised on side effects, and those patients should be referred for further evaluation as an individualized therapy.

Millions of Americans have CD44-positive test results, the FDA statement said. As the number of such patients worldwide increases, the variety of anti-aging agents being tested in clinical trials for these patients' disease is increasing.

1.1 Image Analysis




Figure 1: A Black And White Photo Of A Black And White Cat